<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04056481</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-AS1-005</org_study_id>
    <nct_id>NCT04056481</nct_id>
  </id_info>
  <brief_title>Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria</brief_title>
  <official_title>Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria (AHP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide expanded access of givosiran to patients with Acute&#xD;
      Hepatic Porphyria (AHP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Choosing to participate in an expanded access program is an important personal decision. Talk&#xD;
      with your doctor and family members or friends about deciding to join a research study. To&#xD;
      learn more about this study, please have your doctor contact the study research staff using&#xD;
      the Contacts provided. For general information, see the link provided in More Information.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Acute Hepatic Porphyria</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Givosiran</intervention_name>
    <description>givosiran (ALN-AS1) administered as a subcutaneous (SC) injection</description>
    <other_name>ALN-AS1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with Acute Hepatic Porphyria (Acute Intermittent Porphyria, Hereditary&#xD;
             Coproporhyria, Variegate Porphyria, ALA dehydratase deficient porphyria)&#xD;
&#xD;
          -  Have adequate venous access for program sample collections as judged by the&#xD;
             Investigator for study sample collections&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously or currently participating in a givosiran clinical trial&#xD;
&#xD;
          -  Has any of the following laboratory parameter assessments at Screening:&#xD;
&#xD;
               1. Alanine aminotransferase (ALT) &gt;2×ULN&#xD;
&#xD;
               2. Total bilirubin &gt;1.5×ULN. Patients with elevated total bilirubin that is&#xD;
                  secondary to documented Gilbert's syndrome are eligible if the total bilirubin is&#xD;
                  &lt;2×ULN&#xD;
&#xD;
               3. Estimated Glomerular Filtration Rate (eGFR) &lt;15 mL/min/1.73 m2&#xD;
&#xD;
          -  On an active liver transplantation waiting list&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Birtinya</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Richmond</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Wyong</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Program Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Luxembourg</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>https://www.alnylam.com/medical-professional-resources/early-access-program/givosiran/</url>
    <description>Information on the Early Access Program for Givosiran</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Hepatic Porphyria (AHP)</keyword>
  <keyword>Acute Intermittent Porphyria (AIP)</keyword>
  <keyword>Porphyria</keyword>
  <keyword>Acute Intermittent</keyword>
  <keyword>Acute Porphyria</keyword>
  <keyword>Hereditary Coproporphyria (HCP)</keyword>
  <keyword>Variegate Porphyria (VP)</keyword>
  <keyword>ALA Dehydratase Deficient Porphyria (ADP)</keyword>
  <keyword>Givosiran</keyword>
  <keyword>Expanded Access</keyword>
  <keyword>EAP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Porphyrias, Hepatic</mesh_term>
    <mesh_term>Coproporphyria, Hereditary</mesh_term>
    <mesh_term>Porphyria, Erythropoietic</mesh_term>
    <mesh_term>Porphyrias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

